	Name of the Issue: Akums Drugs and Pharmaceuticals Limited		
1	**Type of Issue**	Initial Public Offer	
2	**Issue Size (Rs. Mn)***	18,567.37	
	**Source: Prospectus dated August 1, 2024*		
3	**Grade of issue along with name of the rating agency**		
	Name	NA	
	Grade	NA	
4	**Subscription Level (Number of times)**	64.64*	
	** excluding Anchor Investor Portion and after removing multiple and duplicate bids*		
	Source: Minutes for basis of allotment dated August 2, 2024		

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%
(i) On Allotment **	12.92
(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2024)	14.86
(iii) at the end of 1st FY (March 31, 2025)	13.17
(iv) at the end of 2nd FY (March 31, 2026)	15.72
(v) at the end of 3rd FY (March 31, 2027) *	Not Available

***Basis of Allotment (excluding pre-issue QIB holding)*

** QIB Holding not disclosed as reporting for relevant period has not been completed.*

6 Financials of the issuer *in Millions*

Parameters	1st FY (March 31,2025)	2nd FY (March 31,2026)	3rd FY (March 31,2027)*
Income from operations	41,181.58	43,590	Not Available
Net Profit/(Loss) for the period	3,821.10	2,564	Not Available
Paid-up equity share capital	306.21	306	Not Available
Reserves excluding revaluation reserves	30,163.93	32,82,727	Not Available

** Financials not available as reporting for the relevant years has not been completed.*

7 Trading Status

The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Frequently
(ii) at the end of 2nd FY (March 31, 2026)	Frequently
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available

** Trading status not disclosed as the relevant fiscal years have not been completed.*

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned

(i) at the end of 1st FY (March 31, 2025)	Mr. Nand Lal Kalra	Cessation due to attaining age
(ii) at the end of 2nd FY (March 31, 2026)	Mr. Anil Kumar Arvindlal Amin	Appointed as Independent Director
(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available

** Changes in Directors of Issuer not updated as the relevant financial years have not been completed*

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

Particulars	Amount proposed to be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2025	Estimated Utilisation of Net Proceeds in Fiscal 2026 and beyond
Repayment/ prepayment of indebtedness of the Company	1,599.10	1,599.10	-
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2,270.90	-	2,270.90
Funding incremental working capital requirements of our Company	550.00	-	550.00
Pursuing inorganic growth initiatives through acquisitions	278.70	-	278.70
General corporate purposes	1,675.00	-	1,675.00
Total Proceeds	**6,373.70**	**1,599.10**	**4,774.60**

(ii) Actual implementation

Particulars	Amount proposed to be financed from Net Proceeds	Actual Utilisation of Net Proceeds	Unutilised Net Proceeds
Repayment/ prepayment of indebtedness of the Company	1,599.10	1,599.10	0.00
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2,270.90	2,270.90	0.00
Funding incremental working capital requirements of our Company	550.00	550.00	0.00
Pursuing inorganic growth initiatives through acquisitions	301.80	301.80	0.00
General corporate purposes	1,700.00	1,700.00	0.00
Total Proceeds	**6,421.80**	**6,421.80**	**0.00**

(iii) Reasons for delay in implementation, if any	Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	During the quarter ended March 31, 2026, unutilised issue expenses of Rs 48.10 million has been reallocated towards the object of - "GCP" by Rs 25.00 million & "Pursuing inorganic growth initiatives through acquisitions" by Rs 23.10 million as actual utilization towards issue expenses is lower than the proposed deployment resulting in an increase in net proceeds. The amount utilised for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1700.00 million). The reallocation of proceeds was duly approved by the Board of Directors of the Company through a resolution dated 13th February 2026. The Company has fully utilized the entire issue proceeds of Rs. 6,800.00 million as on September 30, 2026. Accordingly, no unutilized issue proceeds remain pending for deployment or reimbursement.
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Nil
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Nil

12 Pricing Data

Designated Stock Exchange	NSE
Issue Price (Rs.)	679.00
Listing Date	6-Aug-24

Price parameters	At close of listing day August 06, 2024	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1nd FY after the listing of the issue (31st March,2025)		
				Closing price	High	Low
Market Price	679.00	855.25	845.3	471.1	480.5	466.0
Nifty 50*	23,992.55	25,418.55	23,995.35	23,165.70	23,565.15	23,136.40

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March,2026)			As at the end of the 3rd FY after the listing of the issue (31st March,2027)[1]		
	Closing price	High	Low	Closing price	High	Low
Market Price	466.1	594.0	414.1	Not Available	Not Available	Not Available
Nifty 50*	22,331.4	26,328.6	22,161.6	Not Available	Not Available	Not Available

** Being index of NSE, the designated stock exchange*

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio		Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2025)	At the end of 1st FY (March 31,2026)	At the end of 1st FY (March 31,2027)**
EPS (Diluted)	***Company***					
	Consolidated	2	-0.28	22.60	16.67	Not Available
	Peer Group:					

	Divi's Laboratories	2	60.27	83.20	96.75	
	Suven Pharma (Now Cohance Lifesciences)	1	11.8	10.45	4.68	Not Available
	Gland Pharma	1	46.89	42.40	62.28	Not Available
	Torrent Pharma	5	48.94	56.47	63.92	Not Available
	Alkem Laboratories	2	150.19	181.11	192.51	Not Available
	Eris Lifesciences	1	28.79	25.81	45.26	Not Available
	JB Chemicals	1	34.85	41.56	44.45	Not Available
	Mankind Pharma	1	47.68	49.08	46.28	Not Available
	Innova Captab	10	18.66	22.41	24.63	Not Available
	Industry Avg		49.79	56.94	64.53	Not Available
P/E	***Company***					
	Consolidated	2	NA	20.84	27.96	Not Available
	Peer Group:					
	Divi's Laboratories	2	74.99	66.69	61.35	Not Available
	Suven Pharma (Now Cohance Lifesciences)	1	69.54	102.82	64.41	Not Available
	Gland Pharma	1	42.45	36.68	27.23	Not Available
	Torrent Pharma	5	60.2	56.34	66.02	Not Available
	Alkem Laboratories	2	34.18	26.69	27.53	Not Available
	Eris Lifesciences	1	34.95	53.89	28.66	Not Available
	JB Chemicals	1	51.38	37.30	46.44	Not Available
	Mankind Pharma	1	44.65	50.06	43.34	Not Available
	Innova Captab^	10	29.91	39.76	33.97	Not Available
	Industry Avg		49.14	52.25	44.33	Not Available
RoNW	***Company***					
	Consolidated	2	-0.57%	11.28%	12.54%	Not Available
	Peer Group:					
	Divi's Laboratories	2	11.79%	14.83%	15.32%	Not Available
	Suven Pharma (Now Cohance Lifesciences)	1	14.64%	15.61%	3.84%	Not Available
	Gland Pharma	1	8.85%	7.63%	9.92%	Not Available
	Torrent Pharma	5	24.15%	25.17%	25.49%	Not Available
	Alkem Laboratories	2	17.41%	18.48%	17.01%	Not Available
	Eris Lifesciences	1	15.16%	11.45%	16.36%	Not Available
	JB Chemicals	1	18.90%	19.21%	17.17%	Not Available
	Mankind Pharma	1	20.43%	14.03%	11.89%	Not Available
	Innova Captab	10	11.35%	13.37%	12.92%	Not Available
	Industry Avg		15.85%	15.53%	14.44%	Not Available
NAV per share	***Company***					
	Consolidated	2	49.59	193.59	199.01	Not Available
	Peer Group:					
	Divi's Laboratories	2	511.21	561.08	632.49	Not Available
	Suven Pharma (Now Cohance Lifesciences)	1	80.56	44.35	102.23	Not Available
	Gland Pharma	1	529.65	555.41	628.67	Not Available
	Torrent Pharma	5	202.57	224.29	247.86	Not Available
	Alkem Laboratories	2	862.46	1,002.37	1,156.01	Not Available
	Eris Lifesciences	1	190.12	240.28	281.78	Not Available
	JB Chemicals	1	188.37	220.54	257.33	Not Available

	Mankind Pharma	1	233.73	347.39	394.87	Not Available
	Innova Captab	10	145.2	167.66	190.61	Not Available
	Industry Avg		327.10	373.71	432.43	Not Available

Notes

** Sourced from Prospectus dated August 01, 2024.*

***Not available as the relevant fiscal years have not been completed / information not disclosed*

^ Price as on May 2026

14 Any other material information

Particulars	Date	Remarks
Demand Notice - National Pharmaceuticals Pricing Authority	October 15, 2026	
Mr. Sanjay Kumar, President – Operations, designated as Senior Management Personnel of the Company	November 02, 2026	
Unaudited (standalone & consolidated) financial results for the quarter and half year ended on 30th September, 2026	November 02, 2026	

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com